When CLL patients temporarily stop their BTK inhibitor for a procedure, they can experience a "disease flare" mimicking relapse. It is critical for clinicians to recognize this phenomenon and not misinterpret it as true disease progression, as symptoms typically resolve upon restarting the medication.

When introducing the overall, multi-year treatment plan at the beginning, it helps patients conceptualize myeloma as a chronic condition rather than a series of acute failures. This reframing prepares them for eventual relapse, reducing devastation and helping them see it as the next step in a long journey.

A patient survey reveals a significant evolution in treatment goals. Initially focused on survival and stopping therapy, patients with longer treatment experience and older patients prioritize daily tolerability and quality of life, even over the prospect of treatment-free remission.

The primary goal in Chronic Myeloid Leukemia (CML) has evolved from survival to tolerability and treatment-free remission. These goals are not uniform; younger patients prioritize stopping treatment to start families, while long-term patients increasingly value better tolerability over marginal efficacy gains.

The classic study suggesting >90% adherence is necessary for CML response is outdated. Modern practice shows that controlled dose reductions to improve tolerability can actually lead to better overall outcomes, challenging the idea that perfect adherence to the initial prescribed dose is paramount.

Long-term CML therapy success hinges on adherence. Minor intolerances and lifestyle inconveniences, which accumulate over a lifetime of treatment, are more likely to cause patients to stop therapy than the drug failing to work, compromising outcomes.

For older CLL patients, stopping acalabrutinib after 18 months results in relapse within a year for half of them. However, their overall survival remains identical to those who continue treatment, suggesting a "drug holiday" is a safe option for managing side effects or patient preference without long-term detriment.

Patients are often unprepared that finishing active treatment or achieving "no evidence of disease" is not the end of their struggle. Survivorship introduces a distinct phase of challenges, including managing long-term side effects, PTSD, and fear of recurrence, which requires different support.

The primary goal in CML is evolving from chronic management to achieving Treatment-Free Remission (TFR). This paradigm shift favors using the most potent TKIs, like asciminib, first-line to induce deep, rapid molecular responses and enable eventual therapy discontinuation.